Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. announced the completion of patient enrollment for the interim analysis of its pivotal Phase 3 study evaluating Piclidenoson for moderate-to-severe plaque psoriasis. The study has enrolled 247 patients, and the interim analysis will proceed under a protocol agreed upon with both the FDA and EMA. Results from this analysis are anticipated in Q4 2026 or Q1 2027, marking a significant milestone for the oral drug candidate.

Can-Fite BioPharma Ltd. announced the completion of enrollment for the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for moderate-to-severe plaque psoriasis. The study has now reached the pre-specified interim analysis stage, which will assess efficacy and safety data under a protocol agreed with both the U.S. FDA and the European Medicines Agency (EMA). Results from this analysis are anticipated in Q4 2026 or Q1 2027. Piclidenoson is an oral A3 adenosine receptor agonist with a favorable safety profile, positioning it as a potential new treatment option.

Can-Fite BioPharma announced positive results from its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma. The study met its primary safety endpoint and demonstrated durable overall survival outcomes, with a median overall survival exceeding 5 months in evaluable third-line patients. Notably, one second-line patient remains alive for over 18 months. Based on these findings, Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy.

Can-Fite BioPharma Ltd. announced that the Japan Patent Office has allowed a patent for Namodenoson's anti-obesity technology. This patent covers the use of A3 adenosine receptor agonists, including Namodenoson, for fat loss and treating obesity and related metabolic disorders. This allowance significantly strengthens the company's global intellectual property portfolio in a major pharmaceutical market, complementing existing patents in other key jurisdictions and supporting future partnering opportunities for Namodenoson in the rapidly expanding obesity therapeutics market.

Can-Fite BioPharma announced that the Japan Patent Office has allowed a patent for its lead drug candidate, Namodenoson, for use in achieving fat loss and treating obesity and related metabolic disorders. This allowance significantly strengthens the company's global intellectual property portfolio in a key pharmaceutical market, building on existing patents in other major jurisdictions. Namodenoson, an orally administered A3 adenosine receptor agonist, offers a differentiated mechanism of action in a global obesity therapeutics market projected to exceed $60 billion by 2030.

Can-Fite BioPharma Ltd. announced the publication of a peer-reviewed scientific article in the Biomolecules Journal. The article highlights the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, which are A3 adenosine receptor (A3AR) agonists. The publication reviews evidence supporting A3AR agonist activity across multiple major diseases, including various cancers, metabolic, autoimmune, and neurodegenerative disorders, validating the company's platform technology.

Can-Fite BioPharma Ltd. announced its participation in the BIO International Convention 2026, where it will conduct partnering meetings with pharmaceutical and biotechnology firms. The company aims to discuss licensing and commercialization opportunities for its advanced clinical-stage pipeline, including Namodenoson in pivotal Phase III for HCC and Piclidenoson in pivotal Phase III for psoriasis. Can-Fite's A3 adenosine receptor (A3AR) platform has shown a favorable safety profile, and existing licensing agreements have already generated approximately $20 million in payments.

Can-Fite BioPharma Ltd. announced its participation in the BIO International Convention 2026 to conduct partnering meetings with pharmaceutical and biotechnology firms. The company aims to discuss licensing and commercialization opportunities for its advanced clinical-stage pipeline, which includes Namodenoson for HCC, pancreatic cancer, and MASH, and Piclidenoson for psoriasis and Lowe Syndrome. Can-Fite seeks to expand on its existing regional licensing agreements, which have already generated approximately $20 million in upfront and milestone payments.

Can-Fite BioPharma Ltd. announced that its Annual General Meeting of Shareholders, held on June 4, 2026, successfully approved all five proposals presented. These proposals were detailed in the company's Notice and Proxy Statement, which was furnished to the SEC on April 23, 2026.

Can-Fite BioPharma Ltd. announced positive clinical observations from its ongoing Phase 2a study of namodenoson as a monotherapy for pancreatic cancer. The company highlighted namodenoson's differentiated mechanism of action, including the inhibition of the RAS signaling pathway, which is crucial in pancreatic ductal adenocarcinoma. Enrollment for the study is complete, with several patients demonstrating prolonged disease control, including one patient on therapy for approximately 16 months.